Eesti - eesti - Ravimiamet

g.l. pharma gmbh - pantoprasool - gastroresistentne tablett - 20mg 14tk

Eesti - eesti - Ravimiamet

amomed pharma gmbh - imatiniib - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 90tk; 100mg 180tk; 100mg 120tk; 100mg 60tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibacterials süsteemseks kasutamiseks, - vantobra on näidustatud krooniliste kopsu-nakkuse tõttu pseudomonas aeruginosa patsientidel vanuses 6 aastat ja vanemad koos tsüstiline fibroos (cf). tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - zolpideem - keelealune tablett - 10mg 10tk; 10mg 100tk; 10mg 20tk; 10mg 28tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - aripiprasool - tablett - 10mg 56tk; 10mg 50tk; 10mg 90tk; 10mg 30tk; 10mg 10tk; 10mg 100tk; 10mg 14tk; 10mg 60tk; 10mg 20tk; 10mg 7tk; 10mg 98tk; 10mg 72tk; 10mg 28tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - zolpideem - keelealune tablett - 5mg 100tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - aripiprasool - tablett - 15mg 60tk; 15mg 10tk; 15mg 100tk; 15mg 20tk; 15mg 56tk; 15mg 28tk; 15mg 50tk; 15mg 30tk; 15mg 7tk; 15mg 90tk; 15mg 14tk; 15mg 98tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - tiamiin+püridoksiin+tsüanokobalamiin - õhukese polümeerikattega tablett - 100mg+200mg+0,2mg 20tk; 100mg+200mg+0,2mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Eesti - eesti - Ravimiamet

tad pharma gmbh - dabigatraaneteksilaat - kõvakapsel - 75mg 180tk